Aarhus University Seal / Aarhus Universitets segl

Rasmus Bak

CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Daniel P Dever, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Samantha G Scharenberg, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Joab Camarena, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Eric J Kildebeck, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Joseph T Clark, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Renata M Martin, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Rasmus O Bak
  • Yuming Tang, StemCells Inc, Newark, CA 94560, USA.
  • ,
  • Monika Dohse, StemCells Inc, Newark, CA 94560, USA.
  • ,
  • Johannes A Birgmeier, Department of Developmental Biology, Stanford University, Stanford, CA 94305, USA.
  • ,
  • Karthik A Jagadeesh, Department of Developmental Biology, Stanford University, Stanford, CA 94305, USA.
  • ,
  • Gill Bejerano, Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Department of Developmental Biology, Stanford University, Stanford, CA 94305, USA; Department of Computer Science, Stanford University, Stanford, CA 94305, USA.
  • ,
  • Ann Tsukamoto, ReGen Med Division, BOCO Silicon Valley, Palo Alto, CA 94303, USA.
  • ,
  • Natalia Gomez-Ospina, Department of Pediatrics, Stanford University, Stanford, California 94305, USA.
  • ,
  • Nobuko Uchida, ReGen Med Division, BOCO Silicon Valley, Palo Alto, CA 94303, USA. Electronic address: nobuko.uchida@bocosiliconvalley.com.
  • ,
  • Matthew H Porteus, Department of Pediatrics, Stanford University, Stanford, CA 94305, USA. Electronic address: mporteus@stanford.edu.

Human neural stem cells (NSCs) offer therapeutic potential for neurodegenerative diseases, such as inherited monogenic nervous system disorders, and neural injuries. Gene editing in NSCs (GE-NSCs) could enhance their therapeutic potential. We show that NSCs are amenable to gene targeting at multiple loci using Cas9 mRNA with synthetic chemically modified guide RNAs along with DNA donor templates. Transplantation of GE-NSC into oligodendrocyte mutant shiverer-immunodeficient mice showed that GE-NSCs migrate and differentiate into astrocytes, neurons, and myelin-producing oligodendrocytes, highlighting the fact that GE-NSCs retain their NSC characteristics of self-renewal and site-specific global migration and differentiation. To show the therapeutic potential of GE-NSCs, we generated GALC lysosomal enzyme overexpressing GE-NSCs that are able to cross-correct GALC enzyme activity through the mannose-6-phosphate receptor pathway. These GE-NSCs have the potential to be an investigational cell and gene therapy for a range of neurodegenerative disorders and injuries of the central nervous system, including lysosomal storage disorders.

OriginalsprogEngelsk
TidsskriftiScience
Vol/bind15
Sider (fra-til)524-535
Antal sider12
ISSN2589-0042
DOI
StatusUdgivet - 31 maj 2019
Eksternt udgivetJa

Bibliografisk note

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 155083014